Vical receives $1M Collategene milestone

27 July 2008

US drugmaker Vical has received a further $1.0 million cash payment from its partner, Japan's AnGes MG, related to the Collategene angiogenesis program.

The firm received an initial upfront payment of the same amount under an exclusive license agreement in 2005, and further advancement may lead to additional milestones and royalty payments. In March, AnGes filed for marketing approval with the Japanese Ministry of Health, Labor and Welfare for the use of Collategene as a treatment for critical limb ischemia, an advanced form of peripheral arterial disease, and for Buerger's disease (Marketletter April 7).

Vical estimates that more than 10 million people in the USA have PAD, a common circulatory problem in which narrowed arteries reduce the blood flow to the limbs. Early symptoms of PAD include intermittent claudication, which is caused by ischemia. Approximately 25% of ischemic patients will progress to develop CLI, which is associated with pain at rest and ulcers, and frequently requires amputation. The health care burden in the USA associated with amputations is estimated to be greater than $10.0 billion per year.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight